Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Vir Biotechnology Lowers FY 2024 Operating Expense Guidance To $580-$610M Due To Workforce Restructuring And Phasing Out Influenza, COVID-19, And T Cell-Based Viral Vector Programs; Includes $90 - $80M In Stock-Based Compensation And $40 - $30M In Restructuring Charges; Excludes Sanofi Transaction Impact, To Be Updated In Q3 2024 Earnings; Approximately 3% Of GAAP Operating Expense Funded By Grants

Author: Benzinga Newsdesk | August 01, 2024 04:22pm

Posted In: VIR